MF
Clinical trials for MF explained in plain language.
Never miss a new study
Get alerted when new MF trials appear
Sign up with your email to follow new studies for MF, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough cancers: first human test of experimental drug begins
Disease control Recruiting nowThis is an early-stage study to test the safety and find the right dose of a new experimental drug, JAB-8263, in adults with advanced cancers that have not responded to standard treatments. The trial will enroll about 152 people with various advanced solid tumors (like lung or ov…
Matched conditions: MF
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug combo aims to tame tough blood cancer when standard treatment Isn't enough
Disease control Recruiting nowThis study is for people with myelofibrosis, a serious bone marrow cancer, who are not getting the best results from their current standard medication (ruxolitinib). It will test if adding a new drug called navtemadlin to the standard treatment works better and is safe. About 600…
Matched conditions: MF
Phase: PHASE3 • Sponsor: Kartos Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug trial aims to shrink spleens and ease suffering in blood cancer patients
Disease control Recruiting nowThis study is testing whether a new tablet called flonoltinib maleate can help people with intermediate- or high-risk myelofibrosis, a serious bone marrow cancer. About 105 participants will take either the new drug or an existing treatment to see which one better reduces spleen …
Matched conditions: MF
Phase: PHASE3 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
Massive 5,000-Person study launches to map the journey of rare blood cancers
Knowledge-focused Recruiting nowThis is a long-term observational study aiming to better understand a group of rare, chronic blood cancers called myeloproliferative neoplasms (MPNs). It will follow 5,000 adults in the U.S. who have been diagnosed with an MPN for at least five years, collecting information from …
Matched conditions: MF
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:40 UTC